<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02703584</url>
  </required_header>
  <id_info>
    <org_study_id>03012016</org_study_id>
    <nct_id>NCT02703584</nct_id>
  </id_info>
  <brief_title>Co Administration of GnRH Agonist and hCG for Final Oocyte Maturation</brief_title>
  <official_title>Co Administration of GnRH Agonist and hCG for Final Oocyte Maturation- A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mount Sinai Hospital, Canada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mount Sinai Hospital, Canada</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      All the studies, demonstrating improved oocyte maturity and high pregnancy rate with the dual
      trigger are all retrospective. The investigators therefore aim to perform a prospective
      randomized controlled study in normal responders, comparing cycles triggered with hCG to
      those triggered with hCG+GnRH agonist.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, randomized, double blinded clinical trial. Patients will undergo standard
      clinical and hormonal investigation as usual for IVF. Patients that will be given the
      standard GnRH antagonist IVF protocol will be prospectively randomized into two groups: 1.
      hCG group- will be triggered for final follicular maturation with hCG (Pregnyl 10,000IU) as
      is usual and placebo (normal saline) - 36 hours prior to oocyte aspiration. 2. The Double
      trigger group- will receive GnRH agonist (Suprefact 0.5 mg) and hCG (Pregnyl 10,000IU) 36
      hours prior to the oocyte aspiration. All patients will be supplemented with the usual
      progesterone preparation (vaginal progesterone suppositories) for luteal support.

      In order to increase the rate of MII from to 65% to 80% with an alpha error of 5% and beta
      error of 80% the sample size needed is 276 total patients in both groups or 138 patients in
      each group.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of mature oocytes</measure>
    <time_frame>2 days after randomization</time_frame>
    <description>We will gather the information regarding the number of mature oocytes 2 days after the triggering- ( randomization)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blastocyst rate</measure>
    <time_frame>8 days after the randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">276</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Double trigger</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Triggering of ovulation with GnRH agonist ( Suprefact 0.5mg) + hCG ( Pregnyl 10,000IU)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Triggering of ovulation with hCH ( Pregnyl 10,000IU) + Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buseralin</intervention_name>
    <arm_group_label>Double trigger</arm_group_label>
    <other_name>Suprefact</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>control</arm_group_label>
    <other_name>normal saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pregnyl</intervention_name>
    <arm_group_label>Double trigger</arm_group_label>
    <arm_group_label>control</arm_group_label>
    <other_name>hCG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women during one of their first 3 IVF cycle attempts

          -  Women between the ages of 18-42.

          -  BMI (body mass index) of 18-35.

          -  AMH (Anti mullerian hormone) &gt; 1 ng/ml

          -  FSHË‚ 20 IU/L.

          -  Informed consent.

        Exclusion Criteria:

          -  Women with low ovarian response

          -  Previous enrollment in this study.

          -  AFC&gt;20

          -  E2 above 15,000 pmol/l at the trigger day.

          -  hypersensitive to Suprefact/Pregny/gonal F/Purigon/Menopur/progesterone, and/or their
             ingredients/components of the formulation

          -  primary ovarian failure

          -  pregnancy and breast-feeding

          -  active blood clots

          -  undiagnosed uterine or genital bleeding

          -  endometriosis

          -  uncontrolled hypertension;

          -  uncontrolled diabetes

          -  abnormal liver and kidney functions

          -  abnormal ECG, e.g. QT prolongation and torsades de pointes

          -  cancers/tumors, e.g. pituitary adenomas, ovarian cysts, etc.

          -  HIV, HBV and HCV infections

          -  low bone mineral density (BMD) and an increased risk of bone fracture, such as chronic
             alcohol and/or tobacco use, presumed or strong family history of osteoporosis or
             chronic use of drugs that can reduce bone mass such as anticonvulsants or
             corticosteroids

          -  suicidal tendency, history or disposition to seizures, state of confusion, clinically
             relevant psychiatric disorders, and brain lesions

          -  Use of an investigational drug or participation in an investigational study within 30
             days prior to this study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>41 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert F Casper, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scientific Director TRIO IVF</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jigal Haas, MD</last_name>
    <phone>6478633495</phone>
    <email>jigalh@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>TRIO Fertility</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2K4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jigal Haas</last_name>
      <phone>6478633495</phone>
      <email>jigalh@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2016</study_first_submitted>
  <study_first_submitted_qc>March 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2016</study_first_posted>
  <last_update_submitted>June 28, 2016</last_update_submitted>
  <last_update_submitted_qc>June 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Double trigger</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deslorelin</mesh_term>
    <mesh_term>Chorionic Gonadotropin</mesh_term>
    <mesh_term>Buserelin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

